Govt committee makes recommendations for improving New Zealand's clinical trials environment
This article was originally published in SRA
A parliamentary committee in New Zealand has issued recommendations that it wants the government to act on to improve the country's framework for clinical trials so that it becomes a key destination for research investment1,2.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.